HIMS vs. NTRA, GH, RDNT, OPCH, BTSG, SHC, WGS, CON, PRVA, and SGRY
Should you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Natera (NTRA), Guardant Health (GH), RadNet (RDNT), Option Care Health (OPCH), BrightSpring Health Services (BTSG), Sotera Health (SHC), GeneDx (WGS), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), and Surgery Partners (SGRY). These companies are all part of the "healthcare" industry.
Hims & Hers Health vs. Its Competitors
Hims & Hers Health (NYSE:HIMS) and Natera (NASDAQ:NTRA) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.
Hims & Hers Health presently has a consensus target price of $38.92, suggesting a potential downside of 18.36%. Natera has a consensus target price of $194.00, suggesting a potential upside of 10.00%. Given Natera's stronger consensus rating and higher possible upside, analysts clearly believe Natera is more favorable than Hims & Hers Health.
In the previous week, Natera had 12 more articles in the media than Hims & Hers Health. MarketBeat recorded 34 mentions for Natera and 22 mentions for Hims & Hers Health. Natera's average media sentiment score of 1.41 beat Hims & Hers Health's score of 0.79 indicating that Natera is being referred to more favorably in the news media.
Hims & Hers Health has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
Hims & Hers Health has a net margin of 9.63% compared to Natera's net margin of -12.89%. Hims & Hers Health's return on equity of 26.26% beat Natera's return on equity.
Hims & Hers Health has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.
63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 17.7% of Hims & Hers Health shares are held by company insiders. Comparatively, 5.6% of Natera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Natera beats Hims & Hers Health on 9 of the 17 factors compared between the two stocks.
Get Hims & Hers Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hims & Hers Health Competitors List
Related Companies and Tools
This page (NYSE:HIMS) was last updated on 9/10/2025 by MarketBeat.com Staff
Free HIMS Stock Alerts